Patents by Inventor Jamie Marie Davis

Jamie Marie Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylalkyl and pyridylalkyl piperazine derivatives
    Publication number: 20040186108
    Abstract: This invention relates to compounds of the formula 1 1
    Type: Application
    Filed: November 7, 2003
    Publication date: September 23, 2004
    Inventors: Stephen Sung Yong Cho, Jamie Marie Davis, James M. Graham, Tracy Fay Gregory, Harry Ralph Howard, Sham Shridhar Nikam, Michael Anthony Walters
  • Heterocyclic substituted piperazines for the treatment of schizophrenia
    Publication number: 20040067960
    Abstract: This invention relates to compounds of the formula 1 1
    Type: Application
    Filed: September 26, 2003
    Publication date: April 8, 2004
    Inventors: Jamie Marie Davis, Tracy Fay Gregory, Michael Anthony Walters
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6462073
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: October 8, 2002
    Assignee: American Home Products Corporation
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6342508
    Abstract: Matrix metalloproteinases (MMps) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: January 29, 2002
    Assignee: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Derek Cecil Cole
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Publication number: 20020006922
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Application
    Filed: July 5, 2001
    Publication date: January 17, 2002
    Applicant: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6197791
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: March 6, 2001
    Assignee: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Jannie Lea Baker, Jeremy Ian Levin
  • N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    Patent number: 6172057
    Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: January 9, 2001
    Assignee: American Cyanamid Company
    Inventors: Aranapakam Mudumbai Venkatesan, George Theodore Grosu, Jamie Marie Davis, Baihua Hu, Derek Cecil Cole, Jannie Lea Baker, Marcy Pamela Jacobson, Matthew Robin O'Dell